A PHASE II, MULTI-CENTER, OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SORAFENIB GIVEN DAILY IN COMBINATION WITH REPEATED 21-DAY CYCLES OF DACARBAZINE (DTIC) CHEMOTHERAPY IN SUBJECTS WITH ADVANCED METASTATIC MELANOMA: